Evaluation of adenovirus-delivered human CD59 as a potential therapy for AMD in a model of human membrane attack complex formation on murine RPE

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 9, 2008, Pages 4126-4136

  Ramo, Kasmir ^a   Cashman, Siobhan M ^a   Kumar Singh, Rajendra ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD147 ANTIGEN; CD59 ANTIGEN; COMPLEMENT MEMBRANE ATTACK COMPLEX; LYMPHOCYTE ANTIBODY;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CELL LYSATE; CELL PROTECTION; CELL VACUOLE; CONTROLLED STUDY; CORNEA; CYTOLYSIS; DRUG EFFICACY; EMBRYO; EX VIVO STUDY; EXPRESSION VECTOR; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETINA INJURY; RETINA MACULA AGE RELATED DEGENERATION; SERUM; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; ADENOVIRUS; ADULT; AGING; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL LINE; CULTURE TECHNIQUE; CYTOLOGY; EMBRYO (ANATOMY); FLOW CYTOMETRY; GENE VECTOR; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA MACULA DEGENERATION;

ADENOVIRIDAE; ADULT; AGING; ANIMALS; ANTIGENS, CD59; CELL CULTURE TECHNIQUES; CELL LINE; COMPLEMENT MEMBRANE ATTACK COMPLEX; EMBRYO, MAMMALIAN; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; MACULAR DEGENERATION; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; PIGMENT EPITHELIUM OF EYE;

EID: 53149105921     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2025     Document Type: Article

References (46)

1. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114:253-262. (Pubitemid 46161820)
2. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol. 2003;18:845-854.
3. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res. 2000;70:441-449. (Pubitemid 30662042)
4. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705-732.
5. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res. 2001;73:887-896.
6. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411-431.
7. Tezel TH, Bora NS, Kaplan HJ. Pathogenesis of age-related macular degeneration. Trends Mol Med. 2004;10:417-420.
8. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2006;51:137-152. (Pubitemid 43269939)
9. Jha P, Bora PS, Bora NS. The role of complement system in ocular diseases including uveitis and macular degeneration. Mol Immunol. 2007;44:3901-3908. (Pubitemid 47337119)
10. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.
11. Hageman GS, Anderson DH, Johnson LV, et al A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102:7227-7232.
12. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419-421. (Pubitemid 40530081)
13. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385-389. (Pubitemid 40530070)
14. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38:458-462.
15. Spencer KL, Hauser MA, Olson LM, et al. Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. Hum Mol Genet. 2007;16:1986-1992. (Pubitemid 47354881)
16. Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357:553-561. (Pubitemid 47236280)
17. Walport MJ. Complement: second of two parts. N Engl J Med. 2001;344:1140-1144.
18. Walport MJ. Complement: first of two parts. N Engl J Med. 2001;344:1058-1066.
19. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol. 2006;176:1305-1310.
20. Miwa T, Song WC. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int Immunopharmacol. 2001;1:445-459. (Pubitemid 32197543)
21. Kim DD, Song WC. Membrane complement regulatory proteins. Clin Immunol. 2006;118:127-136.
22. Zhou J, Jang YP, Kim SR, Sparrow JR. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2006;103:16182-16187. (Pubitemid 44715171)
23. Hansch GM, Hammer CH, Vanguri P, Shin ML. Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci U S A. 1981;78:5118-5121. (Pubitemid 12229684)
24. Shin ML, Hansch G, Hu VW, Nicholson-Weller A. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J Immunol. 1986;136:1777-1782. (Pubitemid 16119590)
25. Takizawa H, Takahashi K, Murakami T, Okada N, Okada H. Species-specific restriction of complement by HRF20 (CD59) generated by cDNA transfection. Eur J Immunol. 1992;22:1943-1946.
26. White RV, Kaufman KM, Letson CS, Platteborze PL, Sodetz JM. Characterization of rabbit complement component C8: functional evidence for the species-selective recognition of C8 alpha by homologous restriction factor (CD59). J Immunol. 1994;152:2501-2508. (Pubitemid 2066882)
27. Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 1990;71:1-9. (Pubitemid 20296064)
28. Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol. 1990;144:3478-3483.
29. Morral N, O'Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A. 1999;96:12816-12821. (Pubitemid 29513585)
30. Kim IH, Józkowicz A, Piedra PA, Oka K, Chan L. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A. 2001;98:13282-13287. (Pubitemid 33051354)
31. Lamartina S, Cimino M, Roscilli G, et al. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy. J Gene Med. 2007;9:862-874. (Pubitemid 47543253)
32. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase 1 clinical trial. Hum Gene Ther. 2006;17:167-176.
33. Chevez-Barrios P, Chintagumpala M, Mieler W, et al. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol. 2005;23:7927-7935. (Pubitemid 46657392)
34. Fallaux FJ, Kranenburg O, Cramer SJ, et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther. 1996;7:215-222. (Pubitemid 26044840)
35. Davies A, Simmons DL, Hale G, et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med. 1989;170:637-654. (Pubitemid 19226653)
36. Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T, Linser PJ. Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. Invest Ophthalmol Vis Sci. 2003;44:1305-1311. (Pubitemid 36297854)
37. Gragoudas ES, Adamis AP, Cunningham ET JR, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816. (Pubitemid 40051904)
38. Burns RP, Feeney-Burns L. Clinico-morphologic correlations of drusen of Bruch's membrane. Trans Am Ophthalmol Soc. 1980;78:206-225. (Pubitemid 11035013)
39. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem. 1990;265:3809-3814. (Pubitemid 20096011)
40. Moskovich O, Fishelson Z. Live cell imaging of outward and inward vesiculation induced by the complement c5b-9 complex. J Biol Chem. 2007;282:29977-29986. (Pubitemid 350035280)
41. Morgan BP, Dankert JR, Esser AF. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol. 1987;138:246-253.
42. Lehto T, Meri S. Interactions of soluble CD59 with the terminal complement complexes: CD59 and C9 compete for a nascent epitope on C8. J Immunol. 1993;151:4941-4949. (Pubitemid 23318548)
43. Meri S, Lehto T, Sutton CW, Tyynelá J, Baumann M. Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis. Biochem J. 1996;316 (pt 3):923-935. (Pubitemid 26278446)
44. Bora NS, Kaliappan S, Jha P, et al. CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J Immunol. 2007;178:1783-1790. (Pubitemid 46154650)
45. Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A. 2006;103:2328-2333. (Pubitemid 43271669)
46. Bora NS, Kaliappan S, Jha P, et al. Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H. J Immunol. 2006;177:1872-1878. (Pubitemid 44092526)